Exosomes/miRNAs as mediating cell-based therapy of stroke

Hongqi Xin1*, Yi Li1 and Michael Chopp1,2

1 Department of Neurology, Henry Ford Hospital, Detroit, MI, USA
2 Department of Physics, Oakland University, Rochester, MI, USA

INTRODUCTION

The therapeutic effects of cell-based therapy, such as for the treatment of stroke, with multipotent mesenchymal stromal cells (MSCs) have demonstrated particular promise. Systemic administration of MSCs as a treatment for stroke (Chen et al., 2001a,b; Li et al., 2001; Chopp and Li, 2002; Hessvik et al., 2013), has demonstrated that MSCs promote central nervous system (CNS) plasticity and neurovascular remodeling which lead to functional benefit (Caplan and Dennis, 2006; Zhang et al., 2006b; Chopp et al., 2008; Zhang and Chopp, 2013). Though the mechanism which underlie the interaction and communication between the exogenously administered cells, e.g., MSCs, and brain parenchymal cells are not fully understood, the paracrine effect hypothesis has been strengthened by recent evidence that stem cells release extracellular vesicles which elicit similar biological activity to the stem cells themselves (Lai et al., 2011; Camussi et al., 2013; Xin et al., 2013b). These released extracellular lipid vesicles, provide a novel means of intercellular communication (Raposo and Stoorvogel, 2013; Fujita et al., 2014; Record et al., 2014; Turturici et al., 2014; Zhang and Grizzle, 2014). A particularly important class of extracellular vesicles released by stem cells and MSCs, is exosomes, and accumulating data show that MSCs release large amounts of exosomes which mediate the communication of MSCs with other cells (Collino et al., 2010; Hass and Otte, 2012; He et al., 2012; Xin et al., 2012; Lee et al., 2013; Roccaro et al., 2013; Wang et al., 2014). Here, we focus

Cell-based therapy, e.g., multipotent mesenchymal stromal cell (MSC) treatment, shows promise for the treatment of various diseases. The strong paracrine capacity of these cells and not their differentiation capacity, is the principal mechanism of therapeutic action. MSCs robustly release exosomes, membrane vesicles (≈30–100 nm) originally derived in endosomes as intraluminal vesicles, which contain various molecular constituents including proteins and RNAs from maternal cells. Contained among these constituents, are small non-coding RNA molecules, microRNAs (miRNAs), which play a key role in mediating biological function due to their prominent role in gene regulation. The release as well as the content of the MSC generated exosomes are modified by environmental conditions. Via exosomes, MSCs transfer their therapeutic factors, especially miRNAs, to recipient cells, and therein alter gene expression and thereby promote therapeutic response. The present review focuses on the paracrine mechanism of MSC exosomes, and the regulation and transfer of exosome content, especially the packaging and transfer of miRNAs which enhance tissue repair and functional recovery. Perspectives on the developing role of MSC-mediated transfer of exosomes as a therapeutic approach will also be discussed.

Keywords: cell-based therapy, multipotent mesenchymal stromal cell (MSC), Exosome, microRNAs (miRNAs), bio-information transfer, stroke
our discussion on exosomes derived from MSCs, the biogenesis of MSC exosomes, cargo packaging (especially the miRNAs) and intercellular communication, and discuss new opportunities in modifying exosomal cargo to develop exosome-based cell-free therapeutics.

CHARACTERISTIC OF EXOSOMES
Lipid vesicles can be released by various types of cells, and they have been found in the supernatants from a wide variety of cells in culture, as well as in all bodily fluids (Yang et al., 2014; Yellon and Davidson, 2014; Zhang and Grizzle, 2014). The shedding of microvesicles and exosomes is likely a general property of most cells. Initial studies on cell released vesicles were reported in the 1960s (Roth and Luse, 1964; Schrier et al., 1971; Dalton, 1975), and the most common term, exosome, as applied to cell-derived vesicles was first defined by Trams et al. (1981); since they believe that these “exfoliated membrane vesicles may serve a physiologic function” and “it is proposed that they be referred to as exosomes” (Trams et al., 1981), Box 1, nomenclature).

Extracellular released vesicles mainly include exosomes and microvesicles (Momen-Heravi et al., 2013). Exosomes are endocytic origin small-membrane vesicles. Eukaryotic cells periodically engulf small amounts of intracellular fluid in the specific membrane area, forming a small intracellular body called endosome (Thery et al., 2002). The early endosome matures and develops into the late endosome, during the maturation process, the inward budding of the endosomal membrane forms the intraluminal vesicles (ILV) which range in size from approximately 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter. The late endosome containing ILVs is also referred to as, a multivesicular body (MVB) and proteins 30–100 nm in diameter.

Exosome density in sucrose is located at 1.13–1.19 g/ml, and exosomes can be collected by ultracentrifugation at 100,000g (Thery et al., 2006). The exosome membranes are enriched with cholesterol, sphingomyelin, and ceramide which are contained in lipid rafts (Thery et al., 2006). Most exosomes contain conserved proteins such as tetraspanins (CD81, CD63, and CD9), Alix and Tsg101, as well as the unique tissue/cell type specific proteins that reflect their cellular source. A precise and clear distinction between these vesicles (exosomes and microvesicles) is still lacking, and it is technically difficult to definitively separate them from the culture media by currently available methods like ultracentrifugation, density gradient separation, chromatography and immunoaffinity capture methods (Corrado et al., 2013).

Exosomes are released by most cell types under physiological conditions. The amount of exosomes released from MSCs is highly related to cellular proliferation rate, and the exosome production is inversely correlated to the developmental maturity of the MSCs (Chen et al., 2013b). The release of extracellular vesicles can be altered by cellular stress and damage (Hugel et al., 2005; Greenwalt, 2006). Increased release of extracellular vesicles is associated with the acute and active phases of several neurological disorders (Hugel et al., 2005; Horstman et al., 2007). The distinctions between exosomes and other extracellular vesicles (such as microvesicles) are beyond the scope of this review and will not be discussed in detail here.

MSCs ROBUSTLY RELEASE EXOSOMES
Human MSC conditioned medium can reduce myocardial infarct size in patients with acute myocardial infarction (Timmers et al., 2007), and Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium, probably by increasing myocardial perfusion (Timmers et al., 2011). These therapeutic effects were then subsequently attributed to MSC derived exosomes (Lai et al., 2010). Thereafter, MSC exosomes were widely observed and tested in several disease models (Lee et al., 2012; Reis et al., 2012; Xin et al., 2012; Li et al., 2013; Tomasoni et al., 2013; Sdrimas and Kourembanas, 2014; Tan et al., 2014; Zhu et al., 2014).

Compared to other cells, MSCs can produce large amounts of exosomes (Yeo et al., 2013). There are no differences in terms of morphological features, isolation and storage conditions between exosomes derived from MSCs and other sources (Yeo et al., 2013). The MSC is the most prolific exosome producer when compared

Box 1 | Nomenclature.
Currently, the use of the term ‘exosomes’ for MVB-derived extracellular vesicles (EVs) is widely accepted in the field; however, the large variety of EVs secreted by cells and the technical difficulty to definitively discriminate small EVs from exosomes in the culture media using currently available methods has led to the less stringent usage of the term, exosomes. Exosomes are presently characterized as either small EVs (of 30–100 nm diameter) measured by transmission electron microscopy (TEM), or as EVs recovered after 100000g ultracentrifugation. As Gould and Raposo proposed recently, given the absence of perfect identification of EVs’ of endosomal origin, researchers are recommended to explicitly state their use of terms, choose their terms based on precedent and logical argument, and apply them consistently throughout a piece of work (Gould and Raposo, 2013). Since the EVs identified and employed in our studies fulfill the above mentioned two characteristics (i.e., TEM and 100000g ultracentrifugation), therefore, exosomes are likely the primary constituents of the EVs. Here, in this manuscript, we use the term ‘exosomes’ as defined by Trams et al. (Trams et al., 1981), however, we do not exclude the possibility of other non-exosomal microvesicle components within the content of our injected precipitate, and we do not exclude a contribution of non-exosomal microvesicles to mediating stroke recovery.
FIGURE 1 | The generation of MSC exosomes and bio-information shuttling between MSCs and brain parenchymal cells via exosomes.

Exosomes are generated in the late endosomal compartment by inward budding of the limiting membrane of MVB. The exosome-filled MVBs are either fused with the plasma membrane to release exosomes or sent to lysosomes for degradation. Microvesicles are plasma membrane derived particles that are released into the extracellular environment by the direct outward budding and fission of the plasma membrane. The bio-information carried by MSC exosomes then transfer to brain parenchymal cells like astrocytes and neurons. ILV, intraluminal vesicles; MVB, multivesicular body; GC, Golgi complex; RER, rough endoplasmic reticulum.

to other cell types known to produce exosomes (Yeo et al., 2013). By transfecting human ESC-derived mesenchymal stem cells (hESC-MSCs) with a lentivirus carrying myc gene, Chen et al. generated an immortalized hESC-MSCs cell line. Exosomes from MYC-transformed MSCs were able to reduce relative infarct size in a mouse model of myocardial ischemia/reperfusion injury. They found that MYC transformation may be a practical strategy in ensuring an infinite supply of cells for the production of exosomes in the milligram range as either therapeutic agents or delivery vehicles. Additionally, the increased proliferative rate by MYC transformation reduces the time for cell production and thereby reduces production costs. Chen et al. (2011), thus, making MSCs an efficient and effective “factory” for mass production of exosomes.

THE CARGO OF MSC EXOSOMES

Exosomes are complex “living” structures generated by many cell types containing a multitude of cell surface receptors (Shen et al., 2011a; Yang and Gould, 2013), encapsulating proteins, trophic factors, miRNAs, and RNAs (Koh et al., 2010; Lai et al., 2011, 2012, 2013b; Record et al., 2011; Xin et al., 2012; Chen and Lim, 2013; Katakowski et al., 2013; Tomasoni et al., 2013; Yeo et al., 2013). These bioactive molecules can mediate exosomal intercellular communication (Zhang and Grizzle, 2014; Zhang and Wrana, 2014).

The exosome cargo is dependent on the cell type of origin (Raposo and Stoorvogel, 2013). Besides the common surface markers of exosomes, such as CD9 and CD81, MSCs contain specific membrane adhesive molecules, including CD29, CD44, and CD73 that are expressed on the MSC generated exosomes (Lai et al., 2012). Further, the specific conditions of cell preparation affect the exosome cargo (Kim et al., 2005; Park et al., 2010). In the MSC derived exosome, protein components also changed when exosomes were obtained from different MSC cultured media. In their study, Lai et al. found that 379, 432, and 420 unique proteins, detected by means of liquid chromatography-mass spectrometry/mass spectrometry in three independent batches of MSC derived exosomes, and only 154 common proteins are present (Lai et al., 2012). In addition to the protein cargo, RNAs, e.g., messenger RNA (mRNA) and miRNAs are encapsulated in MSC exosomes. MiRNAs encapsulated in MSC-derived microparticles are predominantly in their precursor form (Chen et al., 2010). However, other studies have demonstrated that various miRNAs are present in MSC exosomes, and the miRNA cargo participates in the cell-cell communication to alter the fate of recipient cells (Koh et al., 2010; Xin et al., 2012, 2013c; Katakowski et al., 2013; Lee et al., 2013; Ono et al., 2014).

Environmental challenges, such as activation or stress conditions, influence the composition, biogenesis, and secretion of exosomes. Possibly, exosome secretion is an efficient adaptive
mechanism that cells modulate intracellular stress situations and modify the surrounding environment via the secretion of exosomes. By preconditioning (Yu et al., 2013) or genetic manipulation (Kim et al., 2007b) of dendritic cells, the exosome secretion profile of these cells can be modified. The proteomic profiles of adipocyte-derived exosomes have been characterized (Sano et al., 2014). The authors found that protein content of the exosomes produced from cultured 3T3-L1 adipocytes was changed when they exposed the cells to hypoxic conditions. Quantitative proteomic analysis showed that 231 proteins were identified in the adipocyte-derived exosomes, and the expression levels of some proteins were altered under hypoxic conditions. The total amount of proteins in exosomes increased by 3-4-fold under hypoxic conditions (Sano et al., 2014). Another study found that the miRNA content of dendritic cell exosomes was affected by the maturation of the cells (Montecalvo et al., 2012), and similarly, compared with those from control cells, exosomes from mast cells contain different mRNAs when the cells were exposed to oxidative stress (Eldh et al., 2010). Furthermore, stressed cells that released exosomes conferred resistance against oxidative stress to recipient cells (Eldh et al., 2010), suggesting that cells modulate intracellular stress situations and modify the surrounding environment via the secretion of exosomes. The MSC exosome profile can be modified by pretreatment, as well. When MSCs were in vitro exposed to brain tissue extracted from rats subjected to middle cerebral artery occlusion (MCAo), the miR-133b levels in MSCs and their released exosomes were significantly increased compared to MSCs exposed to normal rat brain tissue extracts (Xin et al., 2012), indicating that MSCs used for stroke treatment will modify their gene expression and subsequently affect their exosome cargo. Thus, there is a feedback between the MSC and its environment, and through which ischemic conditions will modify the exosome contents, and consequently, the secreted exosomes affect and modify the tissue environment. Though we only tested one specific miRNA in our study, it is reasonable to propose that other miRNAs or other cargos of MSC exosome were modified by the post ischemic condition. i.e., other groups also demonstrated that miR-22 in MSC exosomes were enriched following ischemic preconditioning (Feng et al., 2014).

MSC DERIVED EXOSOMES TRANSFER BIO-INFORMATION TO RECIPIENT CELLS VIA miRNA

MiRNAs are non-protein-coding, short ribonucleic acid (usually 18–25 nucleotides) molecules found in eukaryotic cells. Via binding to complementary sequences on target mRNA transcripts, miRNAs post-transcriptionally control gene expression (Bartel, 2004, 2009). MiRNAs constitute a major regulatory gene family in eukaryotic cells (Bartel, 2004; Zhang et al., 2006a, 2007; Fiore et al., 2008). MiRNAs are master molecular switches, concurrently affecting translation of, possibly, hundreds of mRNAs (Cai et al., 2009; Agnati et al., 2010). Over 1000 miRNAs are encoded by the human genome (Bartel, 2004) and they target about 60% of mammalian genes (Lewis et al., 2005; Friedman et al., 2009), and are abundant in many human cell types (Lim et al., 2003). By affecting gene expression, miRNAs are likely involved in most biological processes (Brennecke et al., 2003; Chen et al., 2004; Cuellar and McManus, 2005; Harfe et al., 2005; Lim et al., 2005). Based on the master gene regulation role of miRNAs, though MSC exosomes have the potential for protein cargo transfer (Zhang et al., 2014), we envisage that compared with the delivery of proteins, transfer of miRNA may have dramatic effects on the network of proteins and RNAs of the recipient cells.

Exosomes are well suited for small functional molecule delivery (Zomer et al., 2010). Increasing evidence indicates that they play a pivotal role in cell-to-cell communication (Mathivanan et al., 2010) and act as biological transporters (Denzer et al., 2000; Fevrier and Raposo, 2004; Lotvall and Valadi, 2007; Smalheiser, 2007; Valadi et al., 2007; Mathivanan et al., 2010; Lee et al., 2011; Record et al., 2011; Von Bartheld and Altick, 2011; Mittelbrunn and Sanchez-Madrid, 2012; Boon and Vickers, 2013; Raposo and Stoorvogel, 2013). Importantly, by being encapsulated and contained within the exosomes, the RNA is protected from the digestion of RNAse or trypsin (Valadi et al., 2007). Multiple studies show that exosomes transfer miRNAs to recipient cells (Valadi et al., 2007; Hergenreider et al., 2012). The transferred miRNAs then modify the recipient cell's characteristics. Shimbo et al. introduced synthetic miR-143 into cells, and the miR-143 was enveloped in released exosomes (Shimbo et al., 2014). The secreted exosome-formed miR-143 is transferred to osteosarcoma cells and subsequently significantly reduced the migration of osteosarcoma cells (Shimbo et al., 2014). Recent studies show that MSC exosomes regulate recipient cell protein expression and modify cell characteristics through the miRNA transfer (Xin et al., 2012; Lee et al., 2013; Wang et al., 2014). Exosomal transfer of miR-23b from the bone marrow may promote breast cancer cell dormancy in a metastatic niche (Ono et al., 2014). The master gene regulation role of miRNAs encapsulated within exosomes, determines their major role in the modification of recipient cells.

EXOSOMES SHUTTLE miRNAs AS REGULATORS FOR STROKE RECOVERY AFTER MSC THERAPY

In the nervous system, exosomes mediate cell-cell communication including the transfer of synaptic proteins, mRNAs and microRNAs (Smalheiser, 2007). The role of miRNAs at various stages of neuronal development and maturation has been recently elucidated (Costa-Mattioli et al., 2009; Saba and Schratt, 2010; Olde Loohuis et al., 2012). Numerous miRNAs are expressed in spatially and temporally controlled manners in the nervous system (Kapsimali et al., 2007; Bak et al., 2008; Dogini et al., 2008; Kocerha et al., 2009; Sethi and Lukiw, 2009; Ziu et al., 2011), suggesting that miRNAs have important functions in the gene regulatory networks involved in adult neural plasticity (Sethi and Lukiw, 2009; Liu and Xu, 2011; Mor et al., 2011; Goldie and Cairns, 2012). Stroke induces changes in the miRNA profile of MSCs and within their released exosomes (Jeyaseelan et al., 2008; Lusardi et al., 2014), and miRNAs actively participate in the recovery process after stroke (Liu et al., 2013).

MiR-133b promotes functional recovery in Parkinson’s disease (Kim et al., 2007a) and appears essential for neurite outgrowth and functional recovery after spinal cord injury in adult zebrafish (Yu et al., 2011). Moreover, miR-133b regulates the expression of its targets, connective tissue growth factor (CTGF), a major
inhibitor of axonal growth at injury sites in the CNS in mammals (White and Jakeman, 2008; Duisters et al., 2009) and down-regulates Ras homolog gene family, member A (RhoA) protein expression (Care et al., 2007; Chiba et al., 2009). In our series of studies, we first found that miR-133b is substantially down-regulated in rat brain after MCAo, and MSC administration significantly increased the miR-133b level in the ischemic cerebral tissue. When MSCs were exposed to ischemic brain extracts, the miR-133b level was increased in exosomes released from these MSCs. We then treated primary cultured neurons and astrocytes with these exosomes, and found the miR-133b level in the neurons and astrocytes were increased, suggesting that the exosomes mediate the miR-133b transfer from MSCs to the neurons and astrocytes. Further in vitro knockdown of miR-133b in MSCs directly confirmed that the increased miR-133b level in astrocytes is attributed to their transfer from MSCs to neural cells, and exosomal miR-133b from MSCs significantly increased the neurite branch number and total neurite length (Xin et al., 2012). Compared with administration of normal MSCs, in vivo administration of MSCs with increased or decreased miR-133b (MSCs modified using lentivirus with miR-133b knocked-in or knocked-down) to rats subjected to MCAo resulted in promotion or inhibition of neurite outgrowth, respectively (Xin et al., 2012). Correspondingly, in vitro and in vivo, we also observed the transfer of miR-133b from MSCs to astrocytes via exosomes down-regulated CTGF expression, which may thin the glial scar and benefit neurite outgrowth. In contrast, treatment of stroke in rats with MSCs containing increased miR-133b, inhibited RhoA expression in neurons which enhanced the regrowth of the corticospinal tract after injury (Dergham et al., 2002; Holtje et al., 2009). Down-regulation of CTGF and RhoA by miR-133b stimulated neurite outgrowth and thereby improved functional recovery after stroke (Xin et al., 2012). This proof-of-concept study, provides the first demonstration that MSCs communicate with astrocytes and neurons and regulate neurite outgrowth by transfer of miRNAs (miR-133b) via exosomes. The identification of exosomes released from MSCs as a shuttle that carries miR-133b to astrocytes and neurons after cerebral ischemia helps to explain, at least in-part, how the exogenous MSCs contribute to neurological recovery after stroke. Exosome delivery of functional miRNAs, e.g., miR-133b, that promote neurite outgrowth may show benefit in other neurological diseases, in addition to stroke.

EXOSOMES AS AN ALTERNATIVE THERAPEUTIC CANDIDATE OF MSCs ON STROKE

MSC exosomes serve as a vehicle to transfer protein, mRNA, and miRNA to distant recipient cells, altering the gene expression of the recipient cells. Recently, MSC exosomes have been found to be efficacious in an increasing number of animal models for the treatment of diseases such as liver fibrosis (Li et al., 2013), liver injury (Tian et al., 2014), hypoxic pulmonary hypertension (Lee et al., 2012), acute lung injury (Sdrimas and Kourembanas, 2014; Zhu et al., 2014), acute kidney injury (Gatti et al., 2011; Reis et al., 2012; Tomasoni et al., 2013), and cardiovascular diseases (Lai et al., 2011). We demonstrated that systemic treatment of stroke with cell-free exosomes derived from MSCs significantly improve neurological outcome and contribute to neurovascular remodeling (Xin et al., 2013b). This approach is the first to consider treatment of stroke solely with exosomes.

Development of gene therapy vehicles for diffuse delivery to the brain is one of the major challenges for clinical gene therapy. By using miRNA mimics or antagonists, miRNA-based strategies have recently emerged as a promising therapeutic approach for specific diseases. However, despite its exciting potential, the bottleneck of this approach is delivery of miRNA; an optimal delivery system must be found before their clinical application. Researchers developed a number of miRNA delivery systems (Zhang et al., 2013), including liposomes (Lv et al., 2006), and peptide transduction domain–double-stranded RNA-binding domain (Eguchi and Dowdy, 2009). However, synthetic materials which are employed in the above systems, limited their use. Thus, the advantages of exosomes as delivery systems are apparent; they only contain biogenic substances and are readily transferred into target cells, as well as they have potentially wide utility for the delivery of nucleic acids, and possibly for selectively targeting cells. We and others have shown that MSCs can act as “factories” for the generation of exosomes, and that the cargo within these exosomes, including the miRNAs, may be regulated by altering the genetic character of the MSCs, e.g., by transfecting the MSCs with specific genes (Zomer et al., 2010; Bullerdiek and Flor, 2012; Hu et al., 2012; Katakowski et al., 2013; Xin et al., 2013c). We have also successfully modulated the miRNA content of the MSC generated exosomes and thereby modulated neurovascular plasticity and neurological recovery from stroke (Xin et al., 2013c). Given that MSC exosomes promote recovery (Xin et al., 2013b) and MSCs release exosomes in vivo, we propose that MSC generated exosomes with enhanced expression of beneficial miRNAs (e.g., miR-133b) may provide improved recovery benefits.

Another development direction for the exosome treatment of disease is the targeting of recipient cells. We demonstrate a significant therapeutic and neuroplasticity effect of systemic exosome administration (Xin et al., 2013b). Considering the nano size of exosomes, they likely enter into the brain (Lakhal and Wood, 2011). Adhesive molecules are expressed on the exosome membrane (Clayton et al., 2004), which may facilitate entry into the brain. Thus, systemic exosome administration may be a means by which to deliver the active components of cell-based therapy to the CNS. To improve exosomal targeting, we may also consider engineering and tailoring cell membrane proteins, e.g., the engineering of dendritic cells to express an exosomal membrane protein, Lamp2b, fused to the neuron-specific RVG peptide3 (Alvarez-Erviti et al., 2011). Alvarez-Erviti et al. demonstrated effective delivery of functional siRNA into mouse brain by systemic injection of exosomes, and targeted the exosomes to neurons (Alvarez-Erviti et al., 2011). These data indicate that specifically targeting neural cells is feasible by modifying exosomal membrane proteins.

CONCLUSION AND PROSPECTS

Exosomes derived from MSCs, carry, and transfer their cargo (e.g., miRNAs) to parenchymal cells, and thereby mediate brain plasticity, and the functional recovery from stroke. For the intricate blend of paracrine factors needed, exosomes may be ideal...
carriers for treatment of a complicated disease such as stroke. Specifically modifying the miRNA content of MSC generated exosomes to modulate the therapeutic response for stroke may enhance their therapeutic application.

Cell-based therapies are in clinical trials for stroke and other neurological diseases (Zhou et al., 2013) and there is a robust literature on the efficacy of cell-based therapies for stroke (Hess and Borlongan, 2008). However, there are multiple benefits in transplanting exosomes rather than in transplanting the whole “factory,” the cell, into the body. In contrast to exogenously administered cells delivered systemically, exosomes, given their nano dimension may readily enter the brain and easily pass through the blood brain barrier (BBB) (Alvarez-Erviti et al., 2011; Kooijmans et al., 2012; Anthony and Shiels, 2013; Gheldof et al., 2013; Meckes et al., 2013). Exogenously administered MSCs may have many adverse effects, i.e. tumor modulation and malignant transformation. (Herberts et al., 2011; Wong, 2011), and they may lodge and initially obstruct small vessels in organs (Gao et al., 2001; Chen et al., 2013a). Exosomes given their min size, in contrast, have no vascular obstructive effect, and have no apparent adverse effects.

One case has been reported where exosomes were used for treatment for severe acute graft vs. host disease (Kordelas et al., 2014) in which MSC exosomes did not show any side effects. Side effects of exosome therapies were also not observed in any of the tumor vaccination studies which were performed in humans (Mignot et al., 2006; Viaud et al., 2008). Prion diseases are infectious neurodegenerative disorders linked to the accumulation of the abnormally folded prion protein (PrP) scrapie (PrPsc) in the CNS. Once present, PrPsc catalyzes the conversion of naturally occurring cellular PrP (PrPc) to PrPsc. Recent studies show both PrPc and PrPsc were actively released into the extracellular environment by PrP-expressing cells before and after infection with sheep prions, respectively, and the release associated with exosomes. Even though EV administration appears safe and no side effects have been observed so far, it should be noted, that exosomes may contribute to intercellular membrane exchange and the spread of prions (Fevrier et al., 2004; Klohn et al., 2013). Since fetal calf serum is used for in vitro culturing MSCs and amplifying the exosomes, it may bring the risk of prion disease spreading by exosomes, but this risk may be carried by in vitro cultured MSCs as well. However, the risk associated with exosome therapies is rather low. Table 1 shows the pros and cons of MSCs based therapy and MSC exosomes based therapy.

### Table 1 | Pros and Cons of MSCs based therapy and MSC exosomes based therapy.

#### MSCs BASED THERAPY

| Pros | Cons |
|------|------|
| Living cell; continuously release exosomes or other soluble factors; potency of differentiation and replacement. | |  

#### MSC EXOSOME BASED THERAPY

| Pros | Cons |
|------|------|
| No vascular obstructive effect; no apparent adverse effects; nano size ensure it easily pass through BBB. | None at present |

Technical issues, such as, purity of exosomes must be addressed, since the most common isolation protocol with differential centrifugation and a sucrose gradient yield a heterogeneous product (El Andaloussi et al., 2013; Lai et al., 2013a). Methods for mass exosome isolation should also be developed to reduce costs. For the modified exosome application, the exosome product needs to be extensively characterized, in order to assess its biological function and to avoid adverse effects.

### ACKNOWLEDGMENTS

This work was supported by NIH grants R01 AG037506 (Michael Chopp), R01 NS066041 (Yi Li) and R01 NS081189 (Hongqi Xin).

### REFERENCES

Agnati, L. F., Guidolin, D., Guescini, M., Genedani, S., and Fuxe, K. (2010). Understanding wiring and volume transmission. *Brain Res. Rev.* 64, 137–159, doi: 10.1016/j.brainresrev.2010.03.003

Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakh, S., and Wood, M. J. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat. Biotechnol.* 29, 341–345. doi: 10.1038/nbt.1807

Amano, T., Furuno, T., Hirahima, N., Ohyama, N., and Nakanishi, M. (2001). Dynamics of intracellular granules with CD63-GFP in rat basophilic leukemia cells. *J. Biochem.* 129, 739–744. doi: 10.1093/oxfordjournals.jbchem.a002914

Anthony, D. F., and Shiels, P. G. (2013). Exploiting paracrine mechanisms of tissue regeneration to repair damaged organs. *Transplant. Res.* 2:10, doi: 10.1186/2047-1440-2-10

Bak, M., Silahtaroglu, A., Moller, M., Christensen, M., Rath, M. F., Skryabin, B., et al. (2008). MicroRNA expression in the adult mouse central nervous system. *RNA* 14, 432–444. doi: 10.1261/rna.783108

Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116, 281–297. doi: 10.1016/S0092-8674(04)00045-5

Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. *Cell* 136, 215–233. doi: 10.1016/j.cell.2009.01.002

Boon, R. A., and Vickers, K. C. (2013). Intercellular transport of microRNAs. *Arterioscler. Thromb. Vasc. Biol.* 33, 186–192. doi: 10.1161/ATVBAHA.112.300139

Borlongan, C. V., Glover, L. E., Tajiri, N., Kaneko, Y., and Freeman, T. B. (2011). The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders. *Prog. Neurobiol.* 95, 213–228. doi: 10.1016/j.pneurobio.2011.08.005

Brennecka, J., Hipner, D. R., Stark, A., Russell, R. B., and Cohen, S. M. (2003). bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. *Cell* 113, 25–36. doi: 10.1016/S0092-8674(03)00231-9

Bullerdiek, J., and Flor, I. (2012). Exosome-delivered microRNAs of “chromosome 19 microRNA cluster” as immunomodulators in pregnancy and tumorogenesis. *Mol. Cytogenet.* 5, 27. doi: 10.1186/1755-8166-5-27

Cai, Y., Yu, X., Hu, S., and Yu, J. (2009). A brief review on the mechanisms of miRNA regulation. *Genomics Proteomics Bioinformatics* 7, 147–154. doi: 10.1016/S1567-0229(08)60044-3

Camussi, G., Deregibus, M. C., and Cantaluppi, V. (2013). Role of stem-cell-derived microvesicles in the paracrine action of stem cells. *Biochem. Soc. Trans.* 41, 283–287. doi: 10.1042/BST20121992

Caplan, A. I., and Dennis, J. E. (2006). Mesenchymal stem cells as trophic mediators. *J. Cell. Biochem.* 98, 1076–1084. doi: 10.1002/jcb.20886

Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., et al. (2007). MicroRNA-133 controls cardiac hypertrophy. *Nat. Med.* 13, 613–618. doi: 10.1038/nm.1582

Chen, C. Z., Li, L., Lodish, H. F., and Bartel, D. P. (2004). MicroRNAs modulate hematopoietic lineage differentiation. *Science* 303, 83–86. doi: 10.1126/science.1091903

Chen, J., Li, Y., Wang, L., Lu, M., Zhang, X., and Chopp, M. (2001a). Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. *J. Neurosci.* 189, 49–57. doi: 10.1016/S0022-510X(01)00557-3
Chen, J., Li, Y., Wang, L., Zhang, Z., Lu, D., Lu, M., et al. (2001b). Ischemic rat brain extracts induce human marrow stromal cell growth factor production. *Neuropharmacology* 22, 275–279. doi: 10.1016/j.neuroscience.2004.06.003

Chiba, Y., Tanabe, M., Goto, K., Sakai, H., and Misawa, M. (2009). Down-regulation of miR-133A contributes to up-regulation of Rhoc in bronchial smooth muscle cells. *Am. J. Respir. Crit. Care Med.* 180, 713–719. doi: 10.1164/rccm.200903-0325OC

Chopp, M., and Li, Y. (2002). Treatment of neural injury with marrow stromal cells. *Lancet Neurol.* 1, 92–100. doi: 10.1016/S1474-4422(02)00040-6

Collino, F., Deregibus, M. C., Bruno, S., Sterpone, L., Agnemo, G., Viltoto, L., et al. (2010). Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. *PLoS ONE* 5, 1137. doi: 10.1371/journal.pone.0011803

Corsi, E., Racchetti, G., and Meldolesi, J. (2009). Shedding microvesicles: artefacts or more. *Trends Cell Biol.* 19, 43–51. doi: 10.1016/j.tcb.2008.11.003

Cuccu, E., Sossin, W., Friedman, R. C., Burge, C. B., and Bartel, D. P. (2009). Most mammalian miRNAs are conserved targets of microRNAs. *Genome Res.* 19, 92–105. doi: 10.1101/gr.087201.108

Corrado, C., Raimondo, S., Chiesi, A., Ciccia, F., De Leo, G., and Alessandro, R. (2010). Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. *PLoS ONE* 5, 1137. doi: 10.1371/journal.pone.0011803

Dharmasaroja, P. (2009). Bone marrow-derived mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. *Nephrol. Dial. Transplant.* 26, 1474–1483. doi: 10.1093/ndt/gfn015

Dogini, D. B., Ribeiro, P. A., Rocha, C., Pereira, T. C., and Lopes-Cendes, I. (2008). MicroRNA expression profile in murine central nervous system development. *J. Mol. Neurosci.* 35, 331–337. doi: 10.1007/s12031-008-9068-4

Duisters, R. F., Tijssen, A. J., Schroen, B., Leenders, J. J., Lentink, V., Van Der Made, I., et al. (2009). miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. *Circ. Res.* 104, 170–178, 176p following 178. doi: 10.1161/CIRCRESAHA.108.182535

Eguchi, A., and Dowdy, S. F. (2009). siRNA delivery using peptide transduction domains. *Trends Pharmacol. Sci.* 30, 341–345. doi: 10.1016/j.tips.2009.04.009

El Andaloussi, S., Mager, L., Breakefield, X. O., and Wood, M. J. (2013). Extracellular vesicles: biology and emerging therapeutic opportunities. *Nat. Rev. Drug Discov.* 12, 347–357. doi: 10.1038/nrd3978

Ferrand, J., Noel, D., Leheurs, P., Prochazkova-Carlotti, M., Chambonnier, L., Menard, A., et al. (2011). Human bone marrow-derived stem cells acquire epithelial characteristics through fusion with gastrointestinal epithelial cells. *PLoS ONE* 6, e19569. doi: 10.1371/journal.pone.0019569

Fevrier, B., and Raposo, G. (2004). Exosomes: endosomal-derived vesicles shipping extracellular messages. *Curr. Opin. Cell Biol.* 16, 415–421. doi: 10.1016/j.cceb.2004.06.003

Fevrier, B., Vilette, D., Archer, F., Loew, D., Faigle, W., Vidal, M., et al. (2004). Cells release prions in association with exosomes. *Proc. Natl. Acad. Sci. U.S.A.* 101, 9683–9688. doi: 10.1073/pnas.0308413101

Fiore, R., Siegel, G., and Schratt, G. (2008). MicroRNA function in neuronal development, plasticity and disease. *Biochim. Biophys. Acta* 1779, 471–478. doi: 10.1016/j.bbagrm.2007.12.006

Friedman, R. C., Farh, K. K., Burge, C. B., and Bartel, D. P. (2009). Most mammalian miRNAs are conserved targets of microRNAs. *Genome Res.* 19, 92–105. doi: 10.1101/gr.087201.108

Fujita, Y., Yoshioka, Y., Ibou, S., Araya, J., Kuswano, K., and Ochiya, T. (2014). Intercellular communication by extracellular vesicles and their microRNAs in asthma. *Clin. Ther.* 36, 873–881. doi: 10.1016/j.clinthera.2014.05.006

Gao, J., Dennis, J. E., Muzic, R. F., Lundberg, M., and Caplan, A. I. (2001). The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. *Cells Tissues Organs* 169, 12–20. doi: 10.1159/000047856

Gao, Q., Katakowski, M., Chen, X., Li, Y., and Chopp, M. (2005). Human bone marrow stromal cells enhance connexin43 gap junction intercellular communication in cultured astrocytes. *Cell Transplant.* 14, 109–117. doi: 10.1080/0963894041000192205

Goldie, B. J., and Cairns, M. J. (2012). Post-transcriptional trafficking and regulation of neuronal gene expression. *Mol. Neurobiol.* 45, 99–108. doi: 10.1007/s12052-012-0222-0

Gold, S. J., and Raposo, G. (2013). As we wait: coping with an imperfect nomenclature for extracellular vesicles. *J. Extracell. Vesicles* 2:20389. doi: 10.3402/jev.v2i0.20389

Greenwalt, J. T. (2006). The how and why of exocytic vesicles. *Transfus. Sci.* 46, 143–152. doi: 10.1111/j.1537-2995.2006.00692.x

Harfe, B. D., McManus, M. T., Mansfield, J. H., Hornstein, E., and Tabin, C. J. (2005). The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. *Proc. Natl. Acad. Sci. U.S.A.* 102, 10898–10903. doi: 10.1073/pnas.0504384102

Hass, R., and Otte, A. (2012). Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment. *Cell Commun. Signal.* 10, 26. doi: 10.1186/1478-811X-10-26
He, J., Wang, Y., Sun, S., Yu, M., Wang, C., Pei, X., et al. (2012). Bone marrow stem-derived microvesicles protect against renal injury in the mouse remnant kidney model. *Nephrology (Carlton)* 17, 493–500. doi: 10.1111/j.1440-1797.2012.01589.x

Herbert, C. A., Kwa, M. S., and Hermens, H. P. (2011). Risk factors in the development of stem cell therapy. *J. Transl. Med.* 9:29. doi: 10.1186/1475-2869-9-29

Hergenreider, E., Heydt, S., Treguer, K., Boettger, T., Horrevoets, A. J., Zeiher, A. M., et al. (2012). Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. *Nat. Cell Biol.* 14, 249–256. doi: 10.1038/ncb2441

Hermann, D. M., and Chopp, M. (2012). Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. *Lancet Neurol.* 11, 369–380. doi: 10.1016/S1474-4422(12)70039-X

Hess, D. C., and Borlongan, C. V. (2008). Cell-based therapy in ischemic stroke. *Circ. Transplant* 23, 1045–1059. doi: 10.3727/096368913X667709

Hu, G., Drescher, K. M., and Chen, X. M. (2012). Exosomal miRNAs: biological properties and therapeutic potential. *Front. Genet.* 3:56. doi: 10.3389/fgene.2013.00056

Hugel, B., Martinez, M. C., Kunzelmann, C., and Wahlestedt, C. (2009). microRNAs in CNS disorders. *Int. Rev. Neurobiol.* 98, 1193–1201. doi: 10.1016/S0074-7747(07)79010-4

Hu, G., Drescher, K. M., and Chen, X. M. (2012). Exosomal miRNAs: biological properties and therapeutic potential. *Front. Genet.* 3:56. doi: 10.3389/fgene.2013.00056

Holte, M., Djialali, S., Hofmann, F., Munster-Wandowski, A., Hendrix, S., Boato, F., et al. (2009). A 29-amino acid fragment of Clostridium botulinum C3 protein enhances neuronal outgrowth, connectivity, and reinnervation. *FASEB J.* 23, 1115–1126. doi: 10.1096/fj.08-116585

Horstman, L. L., Jy, W., Minagar, A., Bidot, C. J., Jimenez, J. I., Alexander, J. S., et al. (2007). Cell-derived microparticles and exosomes in neuroinflammatory disorders. *Int. Rev. Neurobiol.* 79, 227–268. doi: 10.1007/b0074-7747(07)79010-4

Huss, N. P., Sandvig, K., and Llorente, A. (2013). Exosomal miRNAs as Biomarkers for Prostate Cancer. *Front. Genet.* 4:36. doi: 10.3389/fgene.2013.00036

Klohn, P . C., Castro-Seoane, R., and Collinge, J. (2013). Exosome release from dendritic cells genetically modified to express IL-4. *Regen. Med.* 8, 197–209. doi: 10.1016/j.rem.2013.14

Khalil, S., and Wood, M. J. (2011). Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi. *Expert Rev. Med. Chem.* 11, 239–250. doi: 10.1586/14737175.11.2.239

Lee, J. K., Park, S. R., Jung, B. K., Jeon, Y. K., Lee, Y. S., Kim, M. K., et al. (2013). Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. *PLoS ONE* 8:e84256. doi: 10.1371/journal.pone.0084256

Lee, T. H., D’astl, E., Magnus, N., Al-Nedawi, K., Meehan, B., and Rak, J. (2011). Microvesicles as mediators of intercellular communication in cancer—the emerging science of cellular ‘debris’. *Semin. Immunopathol.* 33, 455–467. doi: 10.1007/s00281-011-0250-3

Lee, C., Mitsialis, S. A., Aslam, M., Vitali, S. H., Vergadi, E., Konstantinou, G., et al. (2012). Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. *Circulation* 126, 2601–2611. doi: 10.1161/CIRCULATIONAHA.112.114173

Lee, J. K., Park, S. R., Jung, B. K., Jeon, Y. K., Lee, Y. S., Kim, M. K., et al. (2013). Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. *PLoS One* 8:e84256. doi: 10.1371/journal.pone.0084256

Li, T., Yan, Y., Wang, B., Qian, H., Zhang, X., Shen, L., et al. (2013). Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. *Stem Cells Dev.* 22, 845–854. doi: 10.1089/scd.2012.0395

Li, Y., Chen, J., Wang, L., Lu, M., and Chopp, M. (2001). Treatment of stroke in rat with intracarotid administration of marrow stromal cells. *Neurology* 56, 1666–1672. doi: 10.1212/00055393-200106160-00006

Li, Y., and Chopp, M. (2009). Marrow stromal cell transplantation in stroke and traumatic brain injury. *Neurosci. Lett.* 456, 120–123. doi: 10.1016/j.neulet.2008.03.096

Liang, X., Ding, Y., Zhang, Y., Tse, H. F., and Lian, Q. (2014). Paracrine mechanisms of mesenchymal Stem cell-based therapy: current status and perspectives. *Cell Transplant.* 23, 1045–1059. doi: 10.3727/096368913X667709

Lim, L. P., Lau, N. C., Barrett-Engle, P., Grimson, A., Schelter, J. M., Castle, J., et al. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target miRNAs. *Nature* 433, 769–773. doi: 10.1038/ nature03135

Lim, L. P., Lau, N. C., Weinstein, E. G., Abdelhakim, A., Yekta, S., Rhoades, M. R., et al. (2003). The microRNAs of Caenorhabditis elegans. *Genes Dev.* 17, 991–1008. doi: 10.1101/gad.1074430

Liu, F. J., Lim, K. Y., Kaur, P., Sepramaniam, S., Armugam, A., Wong, P. T., et al. (2013). microRNAs involved in regulating spontaneous recovery in embryonic stroke model. *PLoS ONE* 8:e66393. doi: 10.1371/journal.pone.0066393

Liu, N. K., and Xu, X. M. (2011). MicroRNA in central nervous system trauma and degenerative disorders. *Physiol. Genomics* 43, 571–580. doi: 10.1152/physiogenomics.00168.2010

Lotvall, J., and Valadi, H. (2007). Cell to cell signalling via exosomes through eRNA. *Cell Adh. Migr.* 1, 152–154. doi: 10.4161/cam.1.3.5114

Lu, D., Li, Y., Mahmood, A., Wang, L., Rafiq, T., and Chopp, M. (2002). Neural and marrow-derived stromal cell sphere transplantation in a rat model of traumatic brain injury. *J. Neurosurg.* 97, 935–940. doi: 10.3171/jns.2002.97.10.9395
Mahmood, A., Lu, D., and Chopp, M. (2004). Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury. J. Neurotrauma 21, 33–39. doi: 10.1089/088775197647295922

Mathivanan, S., Ji, H., and Simpson, R. J. (2010). Exosomes: extracellular organelles important in intercellular communication. J. Proteomics 73, 1907–1920. doi: 10.1016/j.jprot.2010.06.006

Mecsko, D. G. Jr., Gunawardena, H. P., Dekroon, R. M., Heaton, P. R., Edwards, R. H., Ozug, S., et al. (2013). Current methods for the isolation of extracellular vesicles. Biochem. Biophys. Res. Commun. 437, 1093–1100. doi: 10.1016/j.bbrc.2013.11.097

Montecavolo, A., Larregina, A. T., Shufesky, W. J., Stolz, D. B., Sullivan, M. L., Karlsson, J. M., et al. (2012). Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119, 756–766. doi: 10.1182/blood-2011-02-338004

Mor, E., Cabilly, V., Goldshmit, Y., Zalts, H., Modai, S., Edry, L., et al. (2011). Species-specific microRNA roles elucidated following astrocyte activation. Nucleic Acids Res. 39, 3710–3723. doi: 10.1093/nar/gkt1325

Muratdaharan-Chari, V., Clancy, J. W., Sedgwick, A., and D’ouza-Chorey, C. (2010). Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 123, 1603–1611. doi: 10.1242/jcs.064386

Olde Loohuis, N. F., Kos, A., Martens, G. J., Van Bokhoven, H., Nadif Kasri, N., Sethi, P., and Lukiw, W. J. (2009). Micro-RNA abundance and stability in human mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and metastatic potential by secretion of proteins and exosomes. Biochem. Pharmacol. 81, 1171–1182. doi: 10.1016/j.bcp.2011.02.011

Roccaro, A. M., Sacco, A., Maiso, P., Azab, A. K., Tai, Y. T., Reagan, M., et al. (2013). BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123, 1542–1555. doi: 10.1172/JCI66517

Roth, L. L., and Luse, S. A. (1984). Fine structure of the neurohypophysis of the opossum (Didelphis Virginiana). J. Cell. Biol. 20, 459–472. doi: 10.1083/jcb.20.3.459

Shen, L. H., Li, Y., and Chopp, M. (2010). Astrocytic endogenous glial cell derived neurotrophic factor production is enhanced by bone marrow stromal cell transplantation in the ischemic boundary zone after stroke in adult rats. Glia 58, 1074–1081. doi: 10.1002/glia.20988

Shen, L. H., Li, Y., Gao, Q., Savant-Bhonsale, S., and Chopp, M. (2008). Down-regulation of neuroenrin expression in reactive astrocytes promotes axonal regeneration and facilitates the neurorestorative effects of bone marrow stromal cells in the ischemic rat brain. Glia 56, 1747–1754. doi: 10.1002/glia.20722

Shen, L. H., Xin, H., Li, Y., Zhang, R. L., Cui, Y., Zhang, L., et al. (2011b). Endogenous tissue plasminogen activator mediates bone marrow stromal cell-induced neurite remodeling after stroke in mice. Stroke 42, 459–464. doi: 10.1161/STROKEAHA.110.593863

Shimbo, K., Miyaki, S., Ishitobi, H., Kato, Y., Kubo, T., Shimose, S., et al. (2014). Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochim. Biophys. Res. Commun. 445, 381–387. doi: 10.1016/j.bbrc.2014.02.007

Smallheiser, N. R. (2007). Exosomal transfer of proteins and RNAs at synapses in the nervous system. Biol. Direct 2, 35. doi: 10.1186/1751-0612-2-35

Spees, J. L., Olson, S. D., Ylostalo, J., Lynch, P. J., Smith, J., Perry, A., et al. (2003). Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc. Natl. Acad. Sci. U.S.A. 100, 2397–2402. doi: 10.1073/pnas.0347997100

Stoorvogel, W., Kleijmeer, M. J., Geuze, H. J., and Raposo, G. (2002). The biogenesis and function of exosomes. Traffic 3, 321–330. doi: 10.1034/j.1600-0852.2002.30502.x

Tan, C., Yai, R. C., Wong, W., Dan, Y. Y., Lim, S. K., and Ho, H. K. (2014). Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res. Ther. 5, 76. doi: 10.1186/s13287-014-00456-0

Thery, C., Amigorena, S., Raposo, G., and Clayton, A. (2006). Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. Chapter 3, Unit 3.2. doi: 10.1002/0471143030.cb032s30

Thery, C., Regnault, A., Garin, J., Wolfers, J., Zitvogel, L., Ricciardi-Castagnoli, P., et al. (1999). Molecular characterization of dendritic cell-derived exosomes. J. Exp. Med. 189, 1003–1015. doi: 10.1084/jem.19990151

Thery, C., Zitvogel, L., and Amigorena, S. (2002). Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569–579. doi: 10.1038/nri855

Timmers, J., Lim, S. K., Arslan, F., Armstrong, J. S., Hoefer, I. E., Doevendans, P. A., et al. (2007). Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res. 1, 129–137. doi: 10.1016/j.scr.2008.02.002
Xin, H., Li, Y., Shen, L. H., Liu, X., Wang, X., Zhang, J., et al. (2010). Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitates neurite outgrowth after stroke in the mouse. PLoS ONE 5:e90927. doi: 10.1371/journal.pone.0090927

Xu, J., Liu, X., Chen, I., Zacharek, A., Cui, X., Savant-Bhonsale, S., et al. (2010). Cell-cell interaction promotes rat marrow stromal cell differentiation into endothelial cell via activation of TACE/TNF-alpha signaling. Cell Transplant. 19, 43–53. doi: 10.3727/096368909X474339

Yang, J. M., and Gould, S. J. (2013). The cis-acting signals that target proteins to exosomes and microvesicles. Biochem. Soc. Trans. 41, 277–282. doi: 10.1042/BST20120275

Yang, X., Weng, Z., Mendrick, D. L., and Shi, Q. (2014). Circulating extracellular vesicles as a potential source of new biomarkers of drug-induced liver injury. Toxicol. Lett. 225, 401–406. doi: 10.1016/j.toxlet.2014.01.013

Yellon, D. M., and Davidson, S. M. (2014). Exosomes: nanoparticles involved in cardioprotection? Circ. Res. 114, 325–332. doi: 10.1161/CIRCRESAHA.113.300636

Yeo, R. W., Lai, R. C., Zhang, B., Tan, S. S., Yin, Y., Teh, B. J., et al. (2013). Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 65, 336–341. doi: 10.1016/j.addr.2012.07.001

Yu, L., Yang, F., Jiang, L., Chen, Y., Wang, K., Xu, E., et al. (2013). Exosomes with membrane-associated TGF-beta1 from gene-modified dendritic cells inhibit murine EAE independently of MHC restriction. Eur. J. Immunol. 43, 2461–2472. doi: 10.1002/eji.201243295

Yu, Y. M., Gibbs, K. M., Davila, J., Campbell, N., Sung, S., Todorova, T. I., et al. (2011). MicroRNA miR-133b is essential for functional recovery after spinal cord injury in adult zebrafish. Eur. J. Neurosci. 33, 1587–1597. doi: 10.1111/j.1460-9568.2011.07643.x

Zacharek, A., Chen, J., Cui, X., Li, A., Li, Y., Roberts, C., et al. (2007). Angiopoietin1/Tie2 and VEGF/FkI induced by MSC treatment ameliorates angiogenesis and vascular stabilization after stroke. J. Cereb. Blood Flow Metab. 27, 1684–1691. doi: 10.1038/sj.jcbf.9600475

Zhang, B., Pan, X., Cobb, G. P., and Anderson, T. A. (2006a). Plant microRNA: a small regulatory molecule with big impact. Dev. Biol. 289, 3–16. doi: 10.1016/j.ydbio.2005.10.036

Zhang, B., Wang, M., Gong, A., Zhang, X., Xu, X., Zhu, Y., et al. (2014). HuMSC exosome-mediated -Wnt4 signaling is required for cutaneous wound healing. Stem Cells. doi: 10.1002/stem.1771. [Epub ahead of print]

Zhang, B., Wang, Q., and Pan, X. (2007). MicroRNAs and their regulatory roles in animals and plants. J. Cell. Physiol. 210, 279–289. doi: 10.1002/jcp.20669

Zhang, H. G., and Grizzle, W. E. (2014). Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am. J. Pathol. 184, 28–41. doi: 10.1016/j.ajpath.2013.09.027

Zhang, H., Huang, Z., Xu, Y., and Zhang, S. (2006b). Differentiation and neurochemical benefit of the mesenchymal stem cells transplanted into the rat brain following intracerebral hemorrhage. Neurol. Res. 28, 104–112. doi: 10.1179/016164106X191960

Zhang, J., Brodie, C., Li, Y., Zheng, C., Roberts, C., Lu, M., et al. (2009). Bone marrow stromal cell therapy reduces proNGF and p75 expression in mice with experimental autoimmune encephalomyelitis. J. Neurosci. 29, 30–38. doi: 10.1523/JNEUROSCI.0821-08.2009

Zhang, J., and Chopp, M. (2013). Cell-based therapy for ischemic stroke. Expert Opin. Biol. Ther. doi: 10.1517/14712598.2013.804507

Zhang, J., Li, Y., Lu, M., Cui, Y., Chen, J., Noffsinger, L., et al. (2006c). Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J. Neurosci. 34, 587–595. doi: 10.1523/JNEUROSCI.2593-06.2006

Zhang, Y., Wang, Z., and Gemeinhart, R. A. (2013). Progress in microRNA delivery. J. Control. Release. 172, 962–974. doi: 10.1016/j.jconrel.2013.09.015

Zhang, Z. G., and Chopp, M. (2009). Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 8, 491–500. doi: 10.1016/S1474-4422(09)70061-4
Zhou, Y., Xu, H., Xu, W., Wang, B., Wu, H., Tao, Y., et al. (2013). Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res. Ther. 4, 34. doi: 10.1186/scrt194

Zhu, Y. G., Feng, X. M., Abbott, J., Fang, X. H., Hao, Q., Monsel, A., et al. (2014). Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells 32, 116–125. doi: 10.1002/stem.1504

Ziu, M., Fletcher, L., Rana, S., Jimenez, D. F., and Digicaylioglu, M. (2011). Temporal differences in microRNA expression patterns in astrocytes and neurons after ischemic injury. PLoS ONE 6:e14724. doi: 10.1371/journal.pone.0014724

Zomer, A., Vendrig, T., Hopmans, E. S., Van Eijndhoven, M., Middeldorp, J. M., and Pegtel, D. M. (2010). Exosomes: fit to deliver small RNA. Commun. Integr. Biol. 3, 447–450. doi: 10.4161/cib.3.5.12339

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.